References
- Nakahara Y, Hosomi Y, Shibuya M, Mitsufuji H, Katagiri M, Naoki K, etal. Multicenter study of Zolendronic acid administration in non-small-cell lung cancer patients with bone metastasis: Thoracic Oncology Research Group (TORG) 1017. MolClinOncol. 2019 Oct 1;11(4):349–53.
- Landi L, D’Incà F, Gelibter A, Chiari R, Grossi F, Delmonte A, etal. Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer. J Immunother Cancer. 2019 Dec;7(1):1–9.
- Clézardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, et al. Bone metastasis: Mechanisms, therapies, and biomarkers. Physiol Rev. 2021 Jul 1;101(3):797–855.
- Tam AH, Schepers AJ, Qin A, Nachar VR. Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases. Ann Pharmacother. 2021 Jun;55(6):697–704.
- Zhang G, Cheng R, Zhang Z, Jiang T, Ren S, Ma Z, et.al. Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. Sci Rep. 2017 Feb 17;7(1):1–7.
- Belwal CK, Patel J. Solvent-free synthesis for imidazole-1-yl-acetic acid hydrochloride: an intermediate for Zolendronic acid. Asian J Green Chem. 2019;3(4):483–91.
- Zoledronic acid. In: In Depth Answers [Internet database]. Greenwood Village (CO): IBM Corporation; 2022 [cited 2022 Aug 21]. Available from: www.micromedexsolutions.com
- Noronha V, Pinninti R, Patil VM, Joshi A, Prabhash K. Lung cancer in the Indian subcontinent. South Asian J Cancer. 2016;5(03):95–103.
- Malik PS, Raina V. Lung cancer: prevalent trends & emerging concepts. Indian J Med Res. 2015;141(1):5.
- Zhou Y, Yu QF, Peng AF, Tong WL, Liu JM, Liu ZL. The risk factors of bone metastases in patients with lung cancer. Sci Rep. 2017;7(1):1–6.
- Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D’alessandro A, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br. J. Cancer. 2003;88(12):1971–8.
- Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases. Clin. Breast Cancer. 2012;12(4):247–58.